- Home
- WOLF vs ELVN Comparison
WOLF vs ELVN Comparison
Compare WOLF & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WOLF | ELVN |
|---|---|---|
| Founded | 1987 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 2.2B |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WOLF | ELVN |
|---|---|---|
| Price | $22.08 | $52.74 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $14.33 | ★ $43.40 |
| AVG Volume (30 Days) | ★ 3.6M | 904.5K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,385,982,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.43 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 19.00 | N/A |
| 52 Week Low | $1.16 | $14.79 |
| 52 Week High | $80.82 | $55.79 |
Technical Indicators
Market Signals| Indicator | WOLF | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 29.76 | 59.05 |
| Support Level | $15.86 | $25.63 |
| Resistance Level | $22.59 | N/A |
| Average True Range (ATR) | 2.66 | 2.36 |
| MACD | -0.79 | -0.29 |
| Stochastic Oscillator | 1.04 | 51.11 |
Price Performance
Historical ComparisonAbout WOLF Wolfspeed Inc.
Wolfspeed Inc develops and manufactures semiconductor technologies based on silicon carbide (SiC) for power electronics applications. Its product portfolio includes SiC MOSFETs, Schottky diodes, and power modules used in power electronics applications. The company also provides reference designs, evaluation kits, and gate driver boards to support the development and integration of its SiC products across industries such as electric vehicles, renewable energy, and industrial systems.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.